facilities the equipment and maintenance services of BMT Cluster center are to be 100% owned by the Skolkovo Foundation and its wholly owned subsidiary of Skolkovo Foundation

Cluster BMT Centers for Shared Facilities

(CSF) /Centers of Excellence (CeO)

5 key elements of the innovation ecosystem of BMT

2

Community of BMT residents

InfrastructuresRegulatory environment

Institutes of commercialization

Training / Educational Programs

Ecosystem. 5

4 3

2

1

Business incubators Venture Capital Funds Strategic industrial investors Institutional Partners

Experts

Residents of the cluster (project companies)

Association of the resident’s partners (biomedical and pharmaceutical clusters)

Center for formalizing of IP Policy

Service Center of support of the Cluster residents (tax, legal, customs consultants)

Infrastructure link-laboratories

Centers for Shared Facilities (CSF), or Centers of Excellence (CoE)

R & D centers . Key partners

University (educational programs) International traineeship Internships International Conferences/Roadshows

22.05.2011 Confidential 3

Development CSF s. Why in 2011?

▪ CSFs are key elements of Skolkovo ecosystem. ▪ CSFs provide

▪ Infrastructural ground for collaboration with key-partners ▪ Integration of R&D, educational and commercialisation functions ▪ Effective use of Skolkovo budget by preparation the Skolkovo infrastructure for 2014 in 2011.

Effective use of the time required for the city construction. Training and preparation of qualified Skolkovo own professionals on Skolkovo own equipment

▪ Realisation of strategy approved by the SAC and the Board of Trustees. ▪ Collaborators worldwide and in Russia have been identified

▪ Existing R&D centres, ▪ Universities,▪ Institutes (RAS, RAMS, NIH, EU, Japan)

▪ Most of big pharmaceutical and institutional investors (RVK, ROSNANO) expressed interest in CSFs ▪ Opportunity to involve Russian Ministry of Health as a major customer from 2011▪ A big time gap (half a year) between purchase, delivery, and installation of equipment in Russia. To be

able to use it Q1 2012 we need to order it now.▪ CSFs will become integral part of the University biomedical department or Techno park.

2014 2012 - 20132011

Infrastructural Link-Labs (Project based).

Centers for Shared Facilities (CSF) or CoE

Functioning of the BMT infrastructural Ecosystem

Educational programs based on the project companies community and infrastructure partners

Creation of Biomedical Department of Skolkovo University

Projects

Res

iden

ts

Infr

astr

uct

ure

s

Link-labs are based on project companies

activities

Part of the R & D centers establishes on the basis of Centers for

Shared FacilitiesR & D centers with key partners

Un

ive

rsit

y

Develop and implement the modules of special lectures and seminars (including "remote web – courses”)

Inv

es

tors

Re

gu

lato

ry

en

vir

on

me

nt

Co-investors and strategic projects partners

Venture Capital Funds

Institutional Partners (RUSNANO, RVC, VEB)

Creating a network of business incubators

Long-term relationships with strategic investors

Support by the functional units of the FundCreation of service centers of legal assistance based on

Techno park4

CSF development pipeline

21.05.2011 Confidential5

Basic Principles of CSF (CoE) functioning.

CSF research areas should be in the BMT foresights. CSF should provide services, research and educational programmes

1)

Capital expenses for major consumables and equipment are covered by the Fund. Operational budget to be provided by residents companies and external customers.

Infrastructure facilities, the equipment and maintenance services of CSFs are to be 100% owned by the Skolkovo Foundation or/and its wholly owned subsidiary.

3)

Project companies (residents of the Skolkovo Foundation) should have a first right to use CSFs services and competencies4)

CSF should provide and maintain excellence in access to modern biomedical equipment, research infrastructure, highly qualified staff, and services on the world level

5)

2)

Key Performance Indicators(KPI)

Budget of BMT Cluster Existing infrastructure sites (departments

of the universities, scientific research centers)

Project companies/residents of the Skolkovo Foundation

Needs and expectations of key partners (industrial biotech and pharmaceutical corporations), establishing of R&D centers

Existing partners of BMT Cluster

BMT sources KPIs for the BMT

Survey of existing infrastructure in Russia for priority areas (foresights)

Arrangement of a public tender. Choosing the best place /key partner for CSF

Identification of strategic partners (co-investors) to establish for CSF

Creation up to 10 CSFs Creation of 3 R&D centers with key partners,

based on CSF concept

21.05.2011 Confidential

Using existing competencies and adding novel ones.

Research and Development

Existing equipment New Equipment

CSF s(CoEs)

Existing methodologies and techniques

Staff Skills and experience

Commercialisation experience

Existing scientific collaborations

Project companies. CSF customers

New qualified staff

Key partners

Effective management

Innovation projectsEducational and retraining

programmes

7

Services

22.05.2011Confidential

8

CSFs address common needs in biotech and biomedicine processing and cover the most significant areas of competence

Early development Lead optimization Preclinical Clinical - Registration and launch

Transgenome and postgenome technologies

Foresightes: Biomedicineand Bio-pharmaceutics

Complex modeling and simulation. Biomedical Informatics

«Proteomics , and other omics

Preclinical and clinical studies. P4 Medicine. Cancer)

Foresight Bioinformatics

Preclinical. GLP Structural Biology»

Directed evolution Artificial ecosystems Scaling upй Foresight

Industrial biotechnologies Synthetic biology

Regenerative medicine

«MAB and other novel therapies

Infection diseases»

22.05.2011 Confidential 9

CSFs development . First Stage

Planned CSF Competencies Major Collaborator Partners

Trans- and post- genome technologies

1. Recombinant human protein and antibodies production in animal cell cultures.

2. Development of new antibacterial drug based on recombinant proteins.

3. New strategies for anticancer therapies

Institute of Gene Biology, RAS

- ОАО «BinnoFarm» - CVT «ChemRar»- IMG RAN- Cold Spring Harbor Laboratory

(USA) - Waksman Institute (USA) - Ministry of health, Russia

Pre-clinical research. GLP standards

R&D and wide spectrum early (library synthesis, screening, hit-to-lead оoptimization) and late stage (toxicity, long term toxicity) pre-clinical studies using certified animals and high primates (CNS)

IBC RAS (Pushchino) - ОSC «RVC» - ITEB RAS (Pushchino) - Ministry of Health, Russia

Structural Biology. Membrane protein and their complexes

1. Cloning and expression of proteins. Membrane2. Protein purification. Membrane3. Protein crystallisation. Membrane.4. Complex structural analysis of proteins (X-RAY, NMR, neutrons)5. Modelling

MFTI and IBC RAS - Institute of Structural Biology (IBS, France) - EMBL, Grenoble - Research Centre (FZ-Juelich, Germany) - SCRIPPS Institute , (USA) - ONEKSIM GROUP

Centre for modelling in biomedicine

1. Modelling of the structure, mode of action and function of drugs2. Analysis, modelling and simulation of complex biological systems .

Virtual organisms.3. Biomedical informatics and databases4. Computer software for biomedical research5. Modelling and database on genomics, proteomics, metabolomics.

Techno park Skolkovo, IBMC RAMS

- IBMC RAMS - NOVARTIS AG - Astra Zeneca - МSU -Institute of Mathematics SO RAS (Novosibirsk) - Ural Cluster- Ministry of health, Russia

22.05.2011 10

CSFs development . Second Stage

Planned CSF Competencies Collaborators Partners

Pre clinical and clinical research for cancer and autoimmune diseases

1. Personalised profiling and analysis of cancer genomes2. Small purified RNAi 3. Combinatorial immunology with phage and cell libraries screening

IBC RAS - ОАО «PHARMSYNTEZ» - SCRIPPS Institute , (USA) - MSU - SpbMAPO RAMS- Dana Farber Cancer Centre, Harvard

Regenerative Medicine Development, testing and preclinical R&D based on novel stem cells technologies, which include among others Cardio Vascular diseasesNervous system pathologies with different aetiologyBone diseasesAging

Under Development

Proteomics Novel methods of analysis based on proteomics, peptidomics, metabolomics using human liquids in normal and disease states IBMC RAMS

- RSMU Sechenov under development

Synthetic Biology 1. Bioremediation2. Complex methods for directed evolution and 3. Industrial biotechnologies

MSU - University of Edinburgh - Massachusetts University - Okinawa Institute of Science and Technology -DIAGEO Inc. (GB)

22.05.2011 Confidential 11

CSFs. Training and further education programmes.

Planned CSF Planned programmes (Modules)

Trans and Post genome technologies

1. Cloning and mutagenesis2. RNA extraction RT-PCR, libraries creation, SELEX.3. Trans- genome technologies fro higher eukaryotes 4. Creation and screening of libraries5. Protein expression. Extraction methods for peptides and proteins6. Protein research in vivo7. Post translational modification for biopharmaceuticals

Pre clinical studies. GLP standards

1. Foundation for preclinical studies. Safety. 2. Laboratory animals for biomedical studies3. GLP standards

Structural biology 1. Molecular biology and expression of membrane proteins2. Structural biology, biophysics and physics. Membrane3. Crystallography and X-ray analysis4. NMR for protein and protein complexes

Modelling and Biomedical Informatics

1. Bioinformatics2. Systems Biology3. PK/PD , ADMET modelling4. Modelling of drug/target interactions

22.05.2011 Confidential 12

CSF. Basic structural Principles. Sectors and open infrastructure

CSF . Structural Biology. MFTI and IBC RAS

Target identification for structural analysis

Protein Cloning . MFTI-IBC

Expression and refolding. Membrane proteins(IBC)

Structural analysis. Membrane proteins

Protein crystallization. Membrane proteins

Protein purification. (MFTI-IBC)

X-RAY crystallography (MFTI)

Neutron structural analysis (MFTI)

NMR spectroscopy(IBC)

Confocal spectroscopy (MFTI)

Imaging (MFTI)

Computer modelling

Every SCF sector is a self sufficient entity and

can operate independently.

Sectors or/and laboratories could have separate

locations

Skolkovo owned Sectors/Laboratories are self

sufficient and could be re located to Skolkovo

premises in 2014 or earlier.

Modules in the sector have a status of a

standalone laboratory/Unit

CSF’s infrastructural elements developing TODAY creates the basis for FUTURE Innovation Center “Skolkovo”создают базу для будущего Инновационного Центра

2014 2012 - 20132011

IBMC RAMS

Concept and strategy approval

Biomedical Informatics. Modelling and simulation Centre

Creation of CSF

Creation of joint R&D centre with a key partner

Re-location and Integration to the Technopark Skolkovo

22.05.11 Confidential 13

Pre-clinical. GLP

Pushchino science Centre

Trans and post genomic technologies

Creation of joint R&D centre with a key partner

Exterritorial Integration to the Technopark Skolkovo

IBG RAS

Part of CSF sectors become laboratories at the Skolkovo University

Part of CSF sectors become exterritorial units of the Technopark Skolkovo.

Re-location and Integration to the Technopark Skolkovo and to the Skolkovo University

Structural biology. Membrane Proteins

MFTI and IBC RAS

22.05.2011 Confidential

14

CSF.Example. Scientific Councils

Skolkovo Foundation

SAC Skolkovo BMT Cluster

External expertsScientific council of major

partner(s)Scientific collaborators of

major partners(s)

Scientific Expert Council

CSF Scientific Council

Expert council of major partner(s)

CSF Development strategy Planning and management of R&D activities

Educational activities Collaboration with Russian and foreign partners

Example of CSF Scientific Council Composition

5 Skolkovo Fund representatives

5 Major partners representatives

2 Independent representatives

1 Chairman - independent. Elected

22/05.2011 Confidential 15

CSFs. Planned activities for 2011. Approved total budget for CFS = 1 287 353 thousands RR

CSF Main Partner may june july august

septemebr

octobernovemb

erTrans and post genome technologies IBG RAS

Preclinical. GLP stndards Pushchino

Structural Biology MFTI, IBC RASModelling and biomedical Informatics Centre Technopark

Concept approval, structuring, and hiring

Purchase of equipmentCSF launchProteomics IBCM RAMS Regenerative medicine TBDP4 Medicine. Cancer and autoimmune diseases IBC RASInfeection diseases IMB, MFTI, TBD "MAB" Generium, TBD Synthetic Biology MSU, TBD

Concept approval, structuring, and hiring

Purchase of equipmentCSF launch